Integration of DC vaccination in the primary treatment of adults with GBM: Update of the Pilot-Trial and the HGG-2006 phase I/II trial

A. Hilko, S. Van Gool, W. Maes, F. Van Calenbergh, J. Goffin, J. Van Loon & S. De Vleeschouwer
Objective: In spite of neurosurgery, radiochemotherapy (RCT) and maintenance temozolomide chemotherapy (TZMm), the prognosis of patients with GBM remains poor. Because immunotherapy opened new perspectives for patients at time of relapse, we are integrating immunotherapy in the primary postoperative[for full text, please go to the a.m. URL]